Navigation Links
Common antifungal drug decreases tumor growth and shows promise as cancer therapy
Date:8/20/2012

AUSTIN, Texas An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows promise as a chemotherapy for cancer. Scientists in the College of Natural Sciences at The University of Texas at Austin made this discovery by exploiting the evolutionary relatedness of yeast, frogs, mice and humans.

Thiabendazole is an FDA-approved, generic drug taken orally that has been in clinical use for 40 years as an antifungal. It is not currently used for cancer therapy.

Hye Ji Cha, Edward Marcotte, John Wallingford and colleagues found that the drug destroys newly established blood vessels, making it a "vascular disrupting agent." Their research was published in the journal PLOS Biology.

Inhibiting blood vessel, or vascular, growth can be an important chemotherapeutic tool because it starves tumors. Tumors induce new blood vessel formation to feed their out-of-control growth.

In trials using mice, the researchers found that thiabendazole decreased blood vessel growth in fibrosarcoma tumors by more than a half. Fibrosarcomas are cancers of the connective tissue, and they are generally heavily vascularized with blood vessels.

The drug also slowed tumor growth.

"This is very exciting to us, because in a way we stumbled into discovering the first human-approved vascular disrupting agent," said Marcotte, professor of chemistry. "Our research suggests that thiabendazole could probably be used clinically in combination with other chemotherapies."

The scientists' discovery is a culmination of research that crosses disciplines and organisms.

In a previous study, Marcotte and his colleagues found genes in single-celled yeast that are shared with vertebrates by virtue of their shared evolutionary history. In yeasts, which have no blood vessels, the genes are responsible for responding to various stresses to the cells. In vertebrates, the genes have been repurposed to regulate vein and arter
'/>"/>

Contact: Lee Clippard
clippard@austin.utexas.edu
512-232-0675
University of Texas at Austin
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Commonly used herbicides seen as threat to endangered butterflies
2. Common North American frog identified as carrier of deadly amphibian disease
3. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
4. New research about facial recognition turns common wisdom on its head
5. Commonly used diabetes drug may help to prevent primary liver cancer
6. Loyola study debunks common myth that urine is sterile
7. Dental X-rays linked to common brain tumor
8. Women & Infants participating in study of treatment of common viral infection in pregnancy
9. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
10. Modest alcohol intake associated with less inflammation in patients with common liver disease
11. Sulphur and iron compounds common in old shipwrecks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common antifungal drug decreases tumor growth and shows promise as cancer therapy
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/18/2014)... has found clownfish larvae can swim up to 400 kilometres ... to cope with environmental change. , Clownfish spend their entire ... as babies they must wander the open ocean, says study ... for Coral Reef Studies (Coral CoE) at James Cook University. ... but now we,ve been given a rare glimpse into how ...
(Date:9/17/2014)... From accessible and affordable health care to reproductive ... depend on the ability of people to identify ... openly and respectfully, and find the most defensible ... practices to support these societal conversations?, The Hastings ... of Bioethical Issues have teamed up to publish ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Researchers at the University of Pennsylvania School of ... with an increased risk of testicular cancer. Testicular cancer is ... among non-Hispanic Caucasian men has doubled in the last 40 ... men in the United States each year. The discovery, published ...
... Carolina State University engineers have created a non-toxic "wrinkled" ... of troublesome barnacles during 18 months of seawater tests, ... of dollars in cleaning and fuel costs. The ... in the Department of Chemical and Biomolecular Engineering, and ...
... ultrafast laser pulses to slice off pieces of ... engineers at the University of Michigan have gained ... division. Their findings could help scientists better ... in plants, fungi, and animalsincluding those in the ...
Cached Biology News:Penn researchers discover genetic risk factor for testicular cancer 2Penn researchers discover genetic risk factor for testicular cancer 3Nontoxic hull coating resists barnacles, may save ship owners millions 2Slicing chromosomes leads to new insights into cell division 2
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Nanotechnology and its potential to revolutionize the ... government agencies, multinational corporations and small start-ups. The ... government funded research projects largely due to the ... capital investments. Government budgets earmarked for this evolving ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... Transgenomic, Inc. (OTC/BB: TBIO) announced today ... company,s high-sensitivity cancer mutation assays using two proprietary ... studies will be presented at the American Association ... April 2-6, 2011. "BLOCker-Sequencing and Ice ...
... New Haven, Conn.Fuel cells have been touted as a ... in everything from cars to computers. But ... their lack of endurance. Over time, the catalysts used ... the chemical reaction that converts fuel into electricity. In ...
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Molecular ... The technologies that constitute ... in situ hybridization (FISH), second-generation biochips and ...
Cached Biology Technology:Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Novel nanowires boost fuel cell efficiency 2Reportlinker Adds Molecular Diagnostics Markets 2Reportlinker Adds Molecular Diagnostics Markets 3Reportlinker Adds Molecular Diagnostics Markets 4Reportlinker Adds Molecular Diagnostics Markets 5Reportlinker Adds Molecular Diagnostics Markets 6Reportlinker Adds Molecular Diagnostics Markets 7Reportlinker Adds Molecular Diagnostics Markets 8Reportlinker Adds Molecular Diagnostics Markets 9Reportlinker Adds Molecular Diagnostics Markets 10Reportlinker Adds Molecular Diagnostics Markets 11Reportlinker Adds Molecular Diagnostics Markets 12Reportlinker Adds Molecular Diagnostics Markets 13Reportlinker Adds Molecular Diagnostics Markets 14Reportlinker Adds Molecular Diagnostics Markets 15Reportlinker Adds Molecular Diagnostics Markets 16Reportlinker Adds Molecular Diagnostics Markets 17Reportlinker Adds Molecular Diagnostics Markets 18
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
... Development kit contains the basic components required ... measure natural and recombinant mouse Dickkopf homolog-1 ... Each kit contains sufficient materials to run ... that the following conditions are met: ...
HIV-1 TAT (vN-21)...
Presenilin-1, N-terminus....
Biology Products: